Department of Dermatology, New York Medical College, Valhalla, NY 10595, USA.
Department of Dermatology, NYC H+Health Hospitals/Metropolitan Hospital Center, New York, NY 10029, USA.
Int J Mol Sci. 2024 Mar 5;25(5):3006. doi: 10.3390/ijms25053006.
Wound healing is an intricate process involving coordinated interactions among inflammatory cells, skin fibroblasts, keratinocytes, and endothelial cells. Successful tissue repair hinges on controlled inflammation, angiogenesis, and remodeling facilitated by the exchange of cytokines and growth factors. Comorbid conditions can disrupt this process, leading to significant morbidity and mortality. Stem cell therapy has emerged as a promising strategy for enhancing wound healing, utilizing cells from diverse sources such as endothelial progenitor cells, bone marrow, adipose tissue, dermal, and inducible pluripotent stem cells. In this systematic review, we comprehensively investigated stem cell therapies in chronic wounds, summarizing the clinical, translational, and primary literature. A systematic search across PubMed, Embase, Web of Science, Google Scholar, and Cochrane Library yielded 22,454 articles, reduced to 44 studies after rigorous screening. Notably, adipose tissue-derived mesenchymal stem cells (AD-MSCs) emerged as an optimal choice due to their abundant supply, easy isolation, ex vivo proliferative capacities, and pro-angiogenic factor secretion. AD-MSCs have shown efficacy in various conditions, including peripheral arterial disease, diabetic wounds, hypertensive ulcers, bullous diabeticorum, venous ulcers, and post-Mohs micrographic surgery wounds. Delivery methods varied, encompassing topical application, scaffold incorporation, combination with plasma-rich proteins, and atelocollagen administration. Integration with local wound care practices resulted in reduced pain, shorter healing times, and improved cosmesis. Stem cell transplantation represents a potential therapeutic avenue, as transplanted stem cells not only differentiate into diverse skin cell types but also release essential cytokines and growth factors, fostering increased angiogenesis. This approach holds promise for intractable wounds, particularly chronic lower-leg wounds, and as a post-Mohs micrographic surgery intervention for healing defects through secondary intention. The potential reduction in healthcare costs and enhancement of patient quality of life further underscore the attractiveness of stem cell applications in wound care. This systematic review explores the clinical utilization of stem cells and stem cell products, providing valuable insights into their role as ancillary methods in treating chronic wounds.
伤口愈合是一个复杂的过程,涉及炎症细胞、皮肤成纤维细胞、角质形成细胞和内皮细胞的协调相互作用。成功的组织修复取决于炎症的控制、血管生成和重塑,这是由细胞因子和生长因子的交换来促进的。合并症会破坏这个过程,导致显著的发病率和死亡率。干细胞疗法已成为增强伤口愈合的一种有前途的策略,利用来自不同来源的细胞,如内皮祖细胞、骨髓、脂肪组织、真皮和诱导多能干细胞。在这个系统评价中,我们全面研究了慢性伤口中的干细胞治疗,总结了临床、转化和原始文献。通过对 PubMed、Embase、Web of Science、Google Scholar 和 Cochrane Library 进行系统搜索,共获得 22454 篇文章,经过严格筛选后减少到 44 项研究。值得注意的是,脂肪组织来源的间充质干细胞(AD-MSCs)由于其丰富的供应、易于分离、体外增殖能力和促血管生成因子分泌而成为最佳选择。AD-MSCs 在各种情况下都显示出疗效,包括外周动脉疾病、糖尿病伤口、高血压性溃疡、大疱性糖尿病、静脉溃疡和 Mohs 显微手术后伤口。输送方法多种多样,包括局部应用、支架结合、与富含血浆的蛋白质结合以及使用类人胶原蛋白。与局部伤口护理实践相结合可减少疼痛、缩短愈合时间并改善美容效果。干细胞移植代表了一种潜在的治疗途径,因为移植的干细胞不仅分化为多种皮肤细胞类型,而且还释放重要的细胞因子和生长因子,促进血管生成增加。这种方法有望用于难治性伤口,特别是慢性小腿伤口,并且作为 Mohs 显微手术后通过二期愈合治疗愈合缺陷的干预措施。潜在的医疗成本降低和患者生活质量的提高进一步突显了干细胞在伤口护理中的应用吸引力。本系统评价探讨了干细胞和干细胞产品的临床应用,为它们作为治疗慢性伤口的辅助方法提供了有价值的见解。